Brooks R A, Gooderham N J, Zhao K, Edwards R J, Howard L A, Boobis A R, Winton D J
Department of Pathology, University of Cambridge, United Kingdom.
Cancer Res. 1994 Apr 1;54(7):1665-71.
Mutations in long lived stem cells are critical events in carcinogenesis. The Dlb-1 assay detects intestinal stem cell mutation at the Dlb-1 locus in Dlb-1a/b heterozygous mice by visualizing mutated clones of epithelial cells in situ which do not bind the lectin Dolichos biflorus agglutinin. We have used this assay to show that the food-derived heterocyclic amine 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a potent intestinal mutagen when administered either i.p. or p.o. This contrasts with the inactivity of the structurally related mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in the assay which we have described previously. Immunocytochemical localization of the P-450 enzyme CYP1A2, which is responsible for the primary activation of these mutagens, shows that in untreated mice it is present in liver hepatocytes and in occasional villus epithelial cells but is absent from the target intestinal stem cell population. In addition, liver microsomes, unlike intestinal microsomes, were able to convert PhIP to the proximate mutagen N-hydroxy-PhIP. CYP1A2 immunoreactivity in beta-napthoflavone-induced animals was elevated in liver hepatocytes and increased to a lesser extent in duodenal villus epithelial cells. Treatment with beta-napthoflavone produced an unexpected 46% decrease in the number of Dlb-1 mutations in response to PhIP. Following treatment with PhIP, there was no difference in the number of Dlb-1 locus mutations between the proximal and distal ends of the small intestine in uninduced animals, indicating that the bile duct is unlikely to be responsible for transport of mutation inducing metabolites of PhIP to the small intestine. Our results demonstrate that metabolic activation of an indirect acting genotoxic agent can occur at a site other than the target tissue, and absence of the enzymes required for activation of a mutagen does not necessarily protect that tissue from its genotoxic effects.
长寿干细胞中的突变是致癌过程中的关键事件。Dlb-1检测法通过可视化不结合凝集素双花扁豆凝集素的上皮细胞突变克隆,来检测Dlb-1a/b杂合小鼠中Dlb-1位点的肠道干细胞突变。我们使用该检测法表明,食物来源的杂环胺2-氨基-1-甲基-6-苯基咪唑并[4,5-b]吡啶(PhIP)经腹腔注射或口服给药时,是一种强效的肠道诱变剂。这与我们之前描述的检测中结构相关的诱变剂2-氨基-3,8-二甲基咪唑并[4,5-f]喹喔啉的无活性形成对比。负责这些诱变剂初级活化的P-450酶CYP1A2的免疫细胞化学定位表明,在未处理的小鼠中,它存在于肝肝细胞和偶尔的绒毛上皮细胞中,但在目标肠道干细胞群体中不存在。此外,与肠道微粒体不同,肝微粒体能够将PhIP转化为近致癌物N-羟基-PhIP。β-萘黄酮诱导的动物中,肝肝细胞中的CYP1A2免疫反应性升高,十二指肠绒毛上皮细胞中的升高程度较小。用β-萘黄酮处理后,对PhIP反应的Dlb-1突变数量意外减少了46%。用PhIP处理后,未诱导动物小肠近端和远端之间Dlb-1位点的突变数量没有差异,这表明胆管不太可能负责将PhIP的诱变代谢物运输到小肠。我们的结果表明,间接作用的遗传毒性剂的代谢活化可以发生在靶组织以外的部位,并且缺乏诱变剂活化所需的酶不一定能保护该组织免受其遗传毒性作用。